Drug Trial Radar · NCT07893171
Study of CM529D1 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
128
Planned (sponsor's estimate)
Start
Nov 27, 2026
Primary completion
Dec 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
CM529D1Biological
CM529D1 will be administered intravenously once every 3 weeks (Q3W) in 6 predetermined dose levels.
CM529D1Biological
CM529D1 will be administered intravenously once every 3 weeks (Q3W) in one or more potential recommended phase 2 dose(RP2D).
CM529D1Biological
CM529D1 will be administered intravenously once every 3 weeks (Q3W) in different types of solid tumor cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)-Phase I dose escalationTime frame: First cycle (21 days)
- Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose escalationTime frame: Through study completion, an average of 2 years
- The Recommended Phase 2 Dose (RP2D)Phase I dose expansionTime frame: Through study completion, an average of 2 years
- Objective response rate (ORR)-Phase IITime frame: Through study completion, an average of 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.